10x Genomics (NASDAQ: TXG) reported Q4 EPS of ($0.15), $0.14 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $156.2 million versus the consensus estimate of $148.06 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.